<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Rifampicin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01045</strong>&#160; (APRD00207, EXPT02777)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits <span class="caps">DNA</span>-dependent <span class="caps">RNA</span> polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of <span class="caps">RNA</span> synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01045/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01045/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01045.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01045.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01045.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01045.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01045.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01045">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>RFP</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rifampin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>USAN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Rifampicin sodium</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001014/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001014/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001014">DBSALT001014</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Rifadin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rifadine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rifaldin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rifoldin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rimactan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rimactane</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rofact</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tubocin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Afracin</td><td>Rifampin + Isoniazid</td></tr><tr><td>IsonaRif</td><td>Isoniazid + Rifampicin</td></tr><tr><td>Rifamate</td><td>Rifampin + Isoniazid</td></tr><tr><td>Rifater</td><td>Isoniazid + Pyrazinaamide + Rifampin</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/enzyme-inhibitors">Enzyme Inhibitors</a></li>
<li><a href="/mesh/antitubercular-agents">Antitubercular Agents</a></li>
<li><a href="/mesh/nucleic-acid-synthesis-inhibitors">Nucleic Acid Synthesis Inhibitors</a></li>
<li><a href="/mesh/leprostatic-agents">Leprostatic Agents</a></li>
<li><a href="/mesh/antibiotics-antitubercular">Antibiotics, Antitubercular</a></li>
<li><a href="/mesh/antibiotics">Antibiotics</a></li></ul></td></tr><tr><th>CAS number</th><td>13292-46-1</td></tr><tr><th>Weight</th><td>Average: 822.9402<br>Monoisotopic: 822.40512334</td></tr><tr><th>Chemical Formula</th><td>C<sub>43</sub>H<sub>58</sub>N<sub>4</sub>O<sub>12</sub></td></tr><tr><th>InChI Key</th><td>JQXXHWHPUNPDRT-WLSIYKJHSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-N-(4-methylpiperazin-1-yl)carboximidoyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Naphthofurans</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Naphthofurans</td></tr><tr><th>Alternative parents</th><td>Naphthols and Derivatives; Benzofurans; Hydroquinones; Ortho Cresols; Toluenes; Alkyl Aryl Ethers; Diazinanes; Piperazines; Hydrazones; Polyols; Ketones; Secondary Carboxylic Acid Amides; Secondary Alcohols; Tertiary Amines; Aldimines; Carboxylic Acid Esters; Enols; Enolates; Carboxylic Acids; Polyamines; Acetals</td></tr><tr><th>Substituents</th><td>1-naphthol; acene; naphthalene; benzofuran; o-cresol; hydroquinone; alkyl aryl ether; toluene; phenol derivative; benzene; piperazine; 1,4-diazinane; hydrazone; ketone; secondary alcohol; secondary carboxylic acid amide; tertiary amine; aldimine; carboxylic acid ester; polyol; carboxamide group; enol; ether; acetal; carboxylic acid; polyamine; carboxylic acid derivative; enolate; carbonyl group; organonitrogen compound; alcohol; imine; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the naphthofurans. These are compounds containing a furan ring fused to a naphthalene moeity.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.</td></tr><tr><th>Pharmacodynamics</th><td>Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including <i>Pseudomonas aeruginosa</i>) and specifically <i>Mycobacterium tuberculosis</i>. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.</td></tr><tr><th>Mechanism of action</th><td>Rifampin acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death.</td></tr><tr><th>Absorption</th><td>Well absorbed from gastrointestinal tract.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>89%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic, rapidly deacetylated.</p></td></tr><tr><th>Route of elimination</th><td>Less than 30% of the dose is excreted in the urine as rifampin or metabolites.</td></tr><tr><th>Half life</th><td>3.35 (+/- 0.66) hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.19 +/- 0.06 L/hr/kg [300 mg IV]</li>
	<li>0.14 +/- 0.03 L/hr/kg [600 mg IV]</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=1570 mg/kg (rat), chronic exposure may cause nausea and vomiting and unconsciousness</td></tr><tr><th>Affected organisms</th><td><ul><li>Mycobacteria</li>
<li>Various gram-negative and gram-positive eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.5553</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.974</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7123</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.9308</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8564</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6049</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8178</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8508</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7296</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8432</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9099</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5803
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8493
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9962
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6875 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.908
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5486
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sanofi aventis us llc</li>
<li>Lannett holdings inc</li>
<li>Sandoz inc</li>
<li>Versapharm inc</li>
<li>Actavis totowa llc</li>
<li>Akorn strides llc</li>
<li>Bedford laboratories div ben venue laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.aaipharma.com">AAIPharma Inc.</a></li>
<li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li>Belgomex Sprl</li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://cibasc.com">Ciba Geigy Ltd.</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Dept Health Central Pharmacy</li>
<li>Eon Labs</li>
<li>Gruppo Lepetit SPA</li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li><a href="http://www.lannett.com">Lannett Co. Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li>Merrell Pharmaceuticals Inc.</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.stridesarco.com">Strides Arcolab Limited</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.versapharm.com">Versapharm Inc.</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Rifampin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00414">Acetohexamide</a></td><td>Rifampin may decrease the effect of sulfonylurea, acetohexamide.</td></tr><tr><td><a href="/drugs/DB00802">Alfentanil</a></td><td>Rifampin reduces levels and efficacy of alfentanil</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Rifampin decreases the effect of theophylline</td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Rifampin decreases the effect of amiodarone</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>In presence of rifampin anticipate decrease of amprenavir efficiency</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Rifampin may decrease the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>The CYP3A4 inducer, rifampin, may decrease the effect of aprepitant.</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Oral administration of rifampin, a strong CYP3A4 inducer, with Coartem Tablets resulted in significant decreases in exposure to artemether, dihydroartemisinin (DHA, metabolite of artemether) and lumefantrine by 89%, 85% and 68%, respectively, when compared to exposure values after Coartem Tablets alone. Concomitant use of strong inducers of CYP3A4 such as rifampin, carbamazepine, phenytoin and St. John&#8217;s wort is contraindicated with Coartem Tablets.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Rifampin reduces levels and efficacy of atazanavir</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Rifampin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01117">Atovaquone</a></td><td>Rifampin may decrease the effect of atovaquone.</td></tr><tr><td><a href="/drugs/DB08903">Bedaquiline</a></td><td>Strong CYP3A4 inducers may decrease exposure of bedaquiline. Co-administration should be avoided. </td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine. </td></tr><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, betamethasone.</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>Rifampin may decrease the serum concentration of bisprolol by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB08873">Boceprevir</a></td><td>Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB06616">Bosutinib</a></td><td>Strong CYP3A4 inducers may decrease levels of bosutinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Rifampin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifampin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01156">Bupropion</a></td><td>Rifampin reduces bupropion levels</td></tr><tr><td><a href="/drugs/DB00490">Buspirone</a></td><td>Rifampin decreases the effect of buspirone</td></tr><tr><td><a href="/drugs/DB06772">Cabazitaxel</a></td><td>Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. </td></tr><tr><td><a href="/drugs/DB08907">Canagliflozin</a></td><td>Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. </td></tr><tr><td><a href="/drugs/DB00520">Caspofungin</a></td><td>Decreased levels/effects of caspofungin</td></tr><tr><td><a href="/drugs/DB00482">Celecoxib</a></td><td>Rifampin, a strong CYP2C9 inducer, may decrease the serum levels of celecoxib by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00439">Cerivastatin</a></td><td>Rifampin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00446">Chloramphenicol</a></td><td>Rifampin decreases the effect of chloramphenicol</td></tr><tr><td><a href="/drugs/DB00672">Chlorpropamide</a></td><td>Rifampin may decrease the effect of sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The rifamycin, rifampin, may decrease the effect of the macrolide, clarithromycin.</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Rifampin decreases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB01380">Cortisone acetate</a></td><td>The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, cortisone acetate.</td></tr><tr><td><a href="/drugs/DB08865">Crizotinib</a></td><td>Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB08865">Crizotinib</a></td><td>Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The rifamycin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB06695">Dabigatran etexilate</a></td><td>P-Glycoprotein inducers such as rifampin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB08912">Dabrafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00250">Dapsone</a></td><td>Decreased levels of dapsone</td></tr><tr><td><a href="/drugs/DB01254">Dasatinib</a></td><td>Rifampin may decrease the serum level and efficacy of dasatinib.</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Rifampin decreases the effect of delavirdine</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, dexamethasone.</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>Rifampin may decrease the effect of the benzodiazepine, diazepam.</td></tr><tr><td><a href="/drugs/DB00586">Diclofenac</a></td><td>Rifampin, a CYP2C9 inducer, may increase the metabolism of diclofenac.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Rifampin may decrease the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Rifampin decreases levels of diltiazem</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>Rifampin decreases the effect of disopyramide</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>The rifamycin decreases the effect of doxycycline</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>Rifampin decreases the effect of theophylline</td></tr><tr><td><a href="/drugs/DB00584">Enalapril</a></td><td>Rifampin, a strong CYP3A4 inducer, may increase the metabolism of enalapril. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of enalapril if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00530">Erlotinib</a></td><td>Decreased levels/effect of erlotinib</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Rifampin decreases the effect of the hydantoin</td></tr><tr><td><a href="/drugs/DB01628">Etoricoxib</a></td><td>Rifampin reduces levels and efficacy of etoricoxib</td></tr><tr><td><a href="/drugs/DB00813">Fentanyl</a></td><td>Rifampin may decrease the serum level and therapeutic effect of fentanyl.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Rifampin may decrease the effect of fluconazole.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01095">Fluvastatin</a></td><td>Rifampin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Rifampin may decrease the effectiveness of fosamprenavir.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Rifampin may decrease the effect of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB08884">Gadoxetate</a></td><td>Substrates of OATP1B1 and OATP1B3 may limit uptake of gadoxetate disodium into heptatocytes. This may alter the intensity of the signal. </td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>Rifampin reduces levels and efficacy of gefitinib</td></tr><tr><td><a href="/drugs/DB01120">Gliclazide</a></td><td>Rifampin may decrease the effect of sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB00222">Glimepiride</a></td><td>Rifampin may decrease the effect of sulfonylurea, glimepiride.</td></tr><tr><td><a href="/drugs/DB01067">Glipizide</a></td><td>Rifampin may decrease the effect of sulfonylurea, glipizide.</td></tr><tr><td><a href="/drugs/DB01289">Glisoxepide</a></td><td>Rifampin may decrease the effect of sulfonylurea, glisoxepide.</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>Rifampin may decrease the effect of sulfonylurea, glibenclamide.</td></tr><tr><td><a href="/drugs/DB01382">Glycodiazine</a></td><td>Rifampin may decrease the effect of sulfonylurea, glycodiazine.</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>The rifamycin decreases the effect of haloperidol</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, hydrocortisone.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Rifampin decreases levels of imatinib</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Rifampin decreases the effect of indinavir</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Rifampin may decrease the effect of itraconazole.</td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>The rifamycin, rifampin, may decrease the effect of the macrolide, josamycin.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Rifampin may decrease the effect of ketoconazole.</td></tr><tr><td><a href="/drugs/DB00555">Lamotrigine</a></td><td>Rifampin decreases levels of lamotrigine</td></tr><tr><td><a href="/drugs/DB01097">Leflunomide</a></td><td>Rifampin increases the effect of leflunomide</td></tr><tr><td><a href="/drugs/DB08882">Linagliptin</a></td><td>CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00678">Losartan</a></td><td>Rifampin decreases the effect of losartan</td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Rifampin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00358">Mefloquine</a></td><td>Rifampin lowers mefloquine levels</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Rifampin decreases the effect of the hydantoin</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>The rifamycin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, methylprednisolone.</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>Rifampin may decrease the serum concentration of metoprolol by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00379">Mexiletine</a></td><td>Rifampin decreases the effect of mexiletine</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Rifampin may increase the metabolism of midazolam. Monitor for changes in the therapeutic and adverse effects of midazolam if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08893">Mirabegron</a></td><td>Strong CYP3A4 inducers may decrease levels of mirabegron. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00295">Morphine</a></td><td>Rifampin decreases the effect of morphine/codeine</td></tr><tr><td><a href="/drugs/DB00688">Mycophenolate mofetil</a></td><td>Rifampin may decrease the serum concentration of mycophenolate. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Rifampin decreases the effect of nelfinavir</td></tr><tr><td><a href="/drugs/DB01115">Nifedipine</a></td><td>Rifampin decreases the effect of the calcium channel blocker, nifedipine.</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB04938">Ospemifene</a></td><td>Rifampin, a strong CYP3A4 / moderate CYP2C9 / moderate CYP2C19 inducer, decreases the systemic exposure of ospemifene by 58%. Therefore, co-administration of ospemifene with drugs such as rifampin which induce CYP3A4, CYP2C9 and/or CYP2C19 activity would be expected to decrease the systemic exposure of ospemifene, which may decrease the clinical effect.</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Rifampin may decrease the effect and toxicity of oxtriphylline.</td></tr><tr><td><a href="/drugs/DB01384">Paramethasone</a></td><td>The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, paramethasone.</td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Concomitant therapy with a CYP3A4 inducer may decrease exposure of pazopanib. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Rifampin may decrease the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB08860">Pitavastatin</a></td><td>Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded. </td></tr><tr><td><a href="/drugs/DB08860">Pitavastatin</a></td><td>Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded. </td></tr><tr><td><a href="/drugs/DB08910">Pomalidomide</a></td><td>Strong CYP3A4 inducers may decrease levels of pomalidomide. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01058">Praziquantel</a></td><td>Significant decrease in praziquantel level</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Rifampin decreases the effect of propafenone</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Rifampin may decrease the serum concentration of propranolol by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Rifampin decreases the effect of quinidine</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>Rifampin decreases the effect of quinidine</td></tr><tr><td><a href="/drugs/DB00980">Ramelteon</a></td><td>Rifampin reduces the levels/effect of ramelteon</td></tr><tr><td><a href="/drugs/DB08896">Regorafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB00912">Repaglinide</a></td><td>Rifampin decreases the effect of repaglinide</td></tr><tr><td><a href="/drugs/DB08864">Rilpivirine</a></td><td>Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Rifampin decreases the effect of ritonavir</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism. </td></tr><tr><td><a href="/drugs/DB00412">Rosiglitazone</a></td><td>Rifampin reduces levels and efficacy of rosiglitazone</td></tr><tr><td><a href="/drugs/DB08877">Ruxolitinib</a></td><td>Strong CYP3A4 inducers may decrease levels of ruxolitinib. Closely monitor patient. </td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Rifampin decreases the effect of saquinavir</td></tr><tr><td><a href="/drugs/DB06335">Saxagliptin</a></td><td>Rifampin is a strong inducer of CYP3A4 which decreases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also increases. </td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Rifampin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>The rifamycin decreases the effect of sirolimus</td></tr><tr><td><a href="/drugs/DB01268">Sunitinib</a></td><td>Possible decrease in sunitinib levels</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Rifampin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Rifampin therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Rifampin may reduce Tadalafil plasma concentrations and efficacy.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>The rifamycin decreases the effect of anti-estrogen</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Strong CYP3A4 inducers will decrease levels of telaprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Rifampin may decrease the plasma concentration of Telithromycin. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Rifampin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Rifampin may increase the metabolism and clearance of Terbinafine. Co-administration may result in Terbinafine treatment failure.</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Rifampin decreases the effect of theophylline</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Rifampin may decrease the plasma concentration of Tipranavir. Concomitant use is not recommended. </td></tr><tr><td><a href="/drugs/DB01056">Tocainide</a></td><td>Rifampin lowers tocainide levels/effects</td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Rifampin (and other potent CYP3A4 inducers), when used in combination with tofacitinib, may decrease tofacitinib toxicity.</td></tr><tr><td><a href="/drugs/DB00839">Tolazamide</a></td><td>Rifampin may decrease the effect of sulfonylurea, tolazamide.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Rifampin may decrease the effect of sulfonylurea, tolbutamide.</td></tr><tr><td><a href="/drugs/DB06212">Tolvaptan</a></td><td>Rifampin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. </td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>The rifamycin decreases the effect of anti-estrogen</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Rifampin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inducer, Rifampin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The strong CYP2C8 inducer, Rifampin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifampin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, triamcinolone.</td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Rifampin may decrease the effect of the benzodiazepine, triazolam.</td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>Rifampin decreases the effect of trimethoprim</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08867">Ulipristal</a></td><td>Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. </td></tr><tr><td><a href="/drugs/DB00313">Valproic Acid</a></td><td>Rifampin may reduce the serum concentration of Valproic acid by increasing Valproic acid metabolism. Valproic acid dose adjustments may be required during concomitant therapy. Monitor Valproic acid serum concentrations, efficacy and toxicity if Rifampin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB05294">Vandetanib</a></td><td>Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  </td></tr><tr><td><a href="/drugs/DB08881">Vemurafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Rifampin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Rifampin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifampin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Rifampin may decrease the anticoagulant effect of warfarin by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00962">Zaleplon</a></td><td>Rifampin decreases the effect of zaleplon</td></tr><tr><td><a href="/drugs/DB00495">Zidovudine</a></td><td>Rifampin may decrease the serum concentration of zidovudine by increasing its metabolism. Monitor for changes in the serum concentration and therapeutic and adverse effects of zidovudine if rifampin is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take on empty stomach: 1 hour before or 2 hours after meals.</li>
<li>Take with a full glass of water.</li></ul></td></tr></tbody></table>